Intraperitoneal cisplatin and doxorubicin as maintenance chemotherapy for unresectable ovarian cancer: a case report

Abstract

BackgroundPrimary advanced, unresectable ovarian cancer (OC) is treated with palliative systemic chemotherapy. Intraperitoneal chemotherapy may be an alternative local maintenance therapy.Case presentationA 75 year old woman with laparoscopically and histologically confirmed unresectable OC was treated with 13 cycles of intraperitoneal cisplatin 7.5 mg/m2 and doxorubicin 1.5 mg/m2 over 2 years using laparoscopic pressurized intraperitoneal aerosol chemotherapy (PIPAC). Objective tumor response (tumor regression on histology, stable disease on repeated video-laparoscopy and peritoneal carcinomatosis index) was noted. No Common Terminology Criteria for Adverse Events (CTCAE) > grade 3 were observed. EORTC QLQ-C30 quality of life measurements were stable throughout the therapy.ConclusionsRepeated intraperitoneal chemotherapy with cisplatin and doxorubicin applied as PIPAC may be an effective maintenance treatment in women with primary advanced, unresectable OC.Electronic supplementary materialThe online version of this article (doi:10.1186/s12885-016-3004-8) contains supplementary material, which is available to authorized users.

Pressurized intraperitoneal aerosol chemotherapy: a review of the introduction of a new surgical technology using the IDEAL framework

“…Overall, the search identified: 23 stage 0 studies; 18 stage 1 studies and two protocol papers for stage 1 studies; 25 stage 2a studies, one protocol paper and five trial registrations (NCT01854255, NCT02735928, NCT03246321, NCT02604784 and NCT03124394) for stage 2a studies; six stage 2b studies and three protocol papers for stage 2b studies; and three protocol papers for stage 3 studies. Fig .…”

Identification of key genes for guiding chemotherapeutic management in ovarian cancer using translational bioinformatics

“…Cisplatin combined with doxorubicin had the smallest proportion of exclusive consensus genes at only 16.2%. Although some studies suggest that it can be used as a standard replacement (4,31,32), when it is used as first-line therapy, with the emergence of drug resistance, the possibility of multi-drug resistance increases, to ensure more drug choices are available for subsequent treatment, this combination is not recommended for first-line chemotherapy.…”

Pressurized intraperitoneal aerosol chemotherapy for recurrent ovarian, fallopian or primary peritoneal cancer with peritoneal carcinomatosis: a narrative review

“…Among 376 patients in nine relevant studies (9,13,15,(23)(24)(25)(26)(27)(28), 200 had recurrent ovarian, fallopian or primary peritoneal cancer with PC. Among them, six studies included mainly the patients with platinum-resistant recurrent disease who received at least one line of previous IV chemotherapy (9,(23)(24)(25)(26)(27), whereas there is a lack of a history of previous treatment before PIPAC in the other three studies. In most studies, the efficacy of PIPAC has been evaluated for patients treated with two or more cycles of PIPAC using doxorubicin and cisplatin.…”

“…For evaluating the accessibility, treatment-related mortality, and toxicity of PIPAC in patients with ovarian, fallopian or primary peritoneal cancer, we found 14 relevant studies (3,9,10,(13)(14)(15)(23)(24)(25)(26)(27)(28)(29)(30). In terms of the accessibility of PIPAC, it was sometimes impossible due to laparoscopic non-access by postoperative adhesion or inability to create a sufficient working chamber.…”